Paper - WANFANG MED ONLINE

You Position: Home > Paper

BRCA1和2基因与卵巢上皮性癌

( views:211, downloads:168 )

Author:: No author available

Journal Title:: CHINESE JOURNAL OF OBSTETRICS AND GYNECOLOGY

Issue:: 1

DOI:: 10.3760/cma.j.issn.0529-567x.2010.01.020

Key Word:: No keyword available

Abstract： @@ 卵巢上皮性癌(卵巢癌)是病死率最高的妇科恶性肿瘤,其发病率随年龄的增长而增加,同时还与体内激素的变化等其他因素相关,而家族史则被认为是最有力的肿瘤预测因素之一.

Reference

[1]饶南燕,周婕,赵林,等.219例中国汉族遗传性乳腺癌患者BRCA1和BRCA2突变的研究[J].2008,(5).
[2]史玉荣,牛瑞芳,魏熙胤,等.卵巢癌患者144例家系调查结果分析[J].2004,(4).
[3]李宁,吴令英,张蓉,等.遗传性乳腺癌卵巢癌91例临床分析[J].2005,(4).
[4]Evans G,Weber BL,Olopade OI,etc.Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.[J].2002,346(21).
[5]Reeves G,Bull D,Beral V.Endometrial cancer and hormone-replacement therapy in the Million Women Study.[J].2005,365(9470).
[6]Marshall M,Solomon S.Hereditary breast-ovarian cancer: clinical findings and medical management.[J].2007,27(3).
[7]Van Horn L,Limacher M,Judd H,etc.Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.[J].2004,291(14).
[8]Patricia A, Roche,George J, Annas.DNA testing, banking, and genetic privacy.[J].2006,355(6).
[9]Roukos DH,Briasoulis E.Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome.[J].2007,4(10).
[10]Offit K,Satagopan JM,Ellis NA,etc.Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.[J].2002,346(21).
[11]J P, Struewing,D, Abeliovich,T, Peretz,etc.The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals.[J].1995,11.
[12]Klijn J,Isaacs C,Wagner T,etc.Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study.[J].2005,23(30).
[13]Rubinstein WS.Surgical management of BRCA1 and BRCA2 carriers: bitter choices slightly sweetened. Clinical Oncology[J].2005,23(31).
[14]McLennan J,Foulkes WD,Lynch HT,etc.Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.[J].2006,296(2).
[15]Smith L,Iddenden R,Moran A,etc.Phenocopies in BRCA1 and BRCA2 families: evidence for modifier genes and implications for screening.[J].2007,44(1).
[16]Brose MS,Nathanson KL,Weber BL,etc.Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program.[J].2002,94(18).
[17]Weber BL,Nathanson KN,Wooster R.Breast cancer genetics: what we know and what we need.[J].2001,7(5).
[18]D B, Berman,J, Costalas,D C, Schultz,etc.A common mutation in BRCA2 that predisposes to a variety of cancers is found in both Jewish Ashkenazi and non-Jewish individuals.[J].1996,56.
[19]B B, Roa,A A, Boyd,K, Volcik,etc.Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2.[J].1996,14.
[20]Janice L. Berliner,Angela Musial Fay.Risk Assessment and Genetic Counseling for Hereditary Breast and Ovarian Cancer: Recommendations of the National Society of Genetic Counselors[J].2007,16(3).
[21]Olopade OI,Armstrong K,Daly MB,etc.Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.[J].2005,23(31).
[22]Lynch H,Ghadirian P,McLaughlin JR,etc.Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.[J].2007,8(1).
[23]A, Berchuck,K A, Heron,M E, Carney,etc.Frequency of germline and somatic BRCA1 mutations in ovarian cancer.[J].1998,4.